# OnCo record keynote-048 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-048/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-048", "NCT02358031" ;
  schema:name "KEYNOTE-048"@en ;
  schema:description "Made immunotherapy the first treatment for advanced head and neck cancer, alone for PD-L1-rich tumours and with chemotherapy for the rest."@en ;
  schema:url <https://onco.cc/trials/keynote-048/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02358031>, <https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32591-7/fulltext> ;
  onco:status "positive" ;
  onco:phase "3" ;
  schema:startDate "2015-03-19" ;
  onco:cancers <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/oropharyngeal-cancer/>, <https://onco.cc/cancers/laryngeal-cancer/>, <https://onco.cc/cancers/oral-cavity-cancer/>, <https://onco.cc/cancers/recurrent-metastatic-hnscc/>, <https://onco.cc/cancers/hypopharyngeal-cancer/>, <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/cps/> ;
  onco:trials <https://onco.cc/trials/extreme/> ;
  onco:people <https://onco.cc/people/barbara-burtness/> .